Spherix Announces Second Quarter 2012 Financial Results
August 13, 2012 13:22 ET
|
Spherix Incorporated
BETHESDA, Md., Aug. 13, 2012 (GLOBE NEWSWIRE) -- Spherix Incorporated (Nasdaq:SPEX) – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider...
Spherix to Hold 2012 Annual Shareholders Meeting on August 14
August 01, 2012 09:11 ET
|
Spherix Incorporated
BETHESDA, Md., Aug. 1, 2012 (GLOBE NEWSWIRE) -- Spherix Incorporated (Nasdaq:SPEX) – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider...
Spherix Reports Findings From New Study in Mice Showing SPX106T Yields Significant Reductions in Serum VLDL
June 27, 2012 12:56 ET
|
Spherix Incorporated
BETHESDA, Md., June 27, 2012 (GLOBE NEWSWIRE) -- Spherix Incorporated (Nasdaq:SPEX) – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider...
Spherix to Present at the 7th LHA Life Sciences & Medical Technologies Virtual Conference on June 28
June 27, 2012 11:24 ET
|
Spherix Incorporated
BETHESDA, Md., June 27, 2012 (GLOBE NEWSWIRE) -- Spherix Incorporated (Nasdaq:SPEX) – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider...
Spherix Announces First Quarter 2012 Financial Results
May 15, 2012 13:45 ET
|
Spherix Incorporated
BETHESDA, Md., May 15, 2012 (GLOBE NEWSWIRE) -- Spherix Incorporated (Nasdaq:SPEX) – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider...